Clinical trial · Observational
Randomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation
HLA-mismatched Peripheral Hematopoietic Stem Cells Infusion in the Treatment of Leukemia Patients Relapse After HLA- Matched Allogeneic Stem Cell Transplantation: A Randomized Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The relapse leukemia patients after transplantation were divided into two groups randomly. Group D1: patients received first-donor stem cells infusion(DSI) treatment with or without chemotherapy; group D2: patients received second-donor DSI treatment with or without chemotherapy. The second donors were preferably donors who were genetically related and had more HLA-match locus. The re-induction chemotherapy regimen was primarily MAT(mitoxantrone, cytarabine, Teniposide ) for acute myeloid leukemia (AML) and VMCLD(vincristine, Teniposide, cyclophosphamide, L-Asparaginase, Dexamethasone) for acute lymphocytic leukemia (ALL), and no graft versus host disease(GVHD) prevention was conducted pre- and post- therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapse Leukemia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| the first donor's stem cell | Biological | — | UNRESOLVED |
| the second donor's stem cell | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- the first donor
- description
- the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy
- interventionNames
- Biological: the first donor's stem cell
- label
- the second donor
- description
- HLA-mismatched, the second donor's stem cell infusion
- interventionNames
- Biological: the second donor's stem cell
Primary outcomes (1)
- measure
- Number of Participants with graft versus host diseases
- timeFrame
- 100 days
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 9 Years
- Maximum age
- 67 Years
Show eligibility criteria text
Inclusion Criteria: * Eligible patients were between 9 and 67 years of age with de novo diagnosed or treated-related Acute leukemia relapsed after HLA-matched hematological stem cell transplantation from Feb 2005 to Feb 2013 * Relapse was morphologically and molecularly diagnosed,with the help of cytogenetic and engraftment. * Eastern Cooperative Oncology Group (ECOG) performance status was 0 to 2 Exclusion Criteria: * Patients without receiving CR will not receive further post-remission trial therapy * The patients of AML-M3 were excluded from this study.
References
Publications (0)
Data not yet available